really good argument and in this day and age, "porque no los dos?", why can't we have both ?
Triangle discounted the cardio protect value by 50%, so why can't we have one BP paying 50% upfront, USD5-8B, and the remaining 50%, $5-8B, paid out in royalties on a sliding scale, ie. majority paid out in bisantrene's patent life and less when generics come into play?
same goes for FTO and $1B AML
certainly a lot more digestible...
AbbVie paid USD22B for only 50% of Pharmacyclics and the other 50% was owned by J&J, instos and SHs who enjoyed royalties/divies of some sort
really good argument and in this day and age, "porque no los...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.31 |
Change
0.020(1.55%) |
Mkt cap ! $217.2M | |||
| Open | High | Low | Value | Volume |
| $1.31 | $1.31 | $1.26 | $71.25K | 55.65K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 200 | $1.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.31 | 5950 | 3 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.31 |
Change
0.020 ( 2.18 %) |
||||
| Open | High | Low | Volume | ||
| $1.30 | $1.31 | $1.26 | 10789 | ||
| Last updated 15.59pm 26/04/2024 ? | |||||
| RAC (ASX) Chart |